SHP-77 In Vitro Genome Sequencing Assay

This assay is to provide SHP-77-based In Vitro Genome Sequencing Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

SHP-77

Human

SHP-77 epithelial cells are derived from a non-encapsulated primary lung tumor from the apical portion of the upper lobe of the left lung of a 54-year-old, White male in 1977. SHP-77 cells can serve as an in vitro target in 51Cr and 111 in release cytotoxicity assays as well as in vivo nude mice assays for evaluating immune reactivity of cells and serum from lung cancer patients. The cells can be used to evaluate the immune status of patients with SCLC who are treated with radiation or chemotherapy.

Lung Cancer

Oncology

In Vitro Genome Sequencing Assay

Genome sequencing is the most accurate and informative method used to identify gene mutations in basic biological and clinical research.

Genome Alteration Assays

Aberrant or somatic mutations are more commonly found in the DNA of cancer cells compared to normal cells. There is an equilibrium that exists between DNA damage and repair in normal cells. However, in cancer cells these events are disturbed, resulting in mutations and genomic instability. Genomic instability in cancer cells causes chromosomal aberrations, microsatellite instability, aneuploidy and uncontrolled gene amplifications and genetic instability in cancer cells are mainly due to point mutations or chromosomal aberrations such as insertions, deletions and translocation, resulting in mutated proteins.